Update on Antithrombin for the Treatment of Burn Trauma and Smoke Inhalation Injury

  • S. Rehberg
  • D. L. Traber
  • P. Enkhbaatar


A severe imbalance of systemic and alveolar hemeostasis, as evidenced by an increase in pro-coagulant and a decrease in anti-fibrinolytic activities, represents a hallmark of burn trauma and smoke inhalation injury [1]. The resulting hypercoagulable state is established within the initial 24 h after the injury and is characterized by high levels of activated factor VII, thrombin-antithrombin complexes, plasminogen activator inhibitor type-1 (PAI-1), and low levels of protein C as well as antithrombin [2]. Plasma levels of antithrombin decrease by 50% in burn patients within the first five days and represent an independent predictor of length of hospital stay and mortality [1, 3]. However, the host response to burn trauma Cl:s well as to smoke inhalation injury, is not only restricted to coagulation disorders, but also includes a marked activation of the inflammation cascade [4]. Both the systemic inflammatory response syndrome (SIRS) and the pro-coagulatory imbalance in hemostasis ultimately result in multiple organ failure (MOF) and increased mortality rates.


Acute Lung Injury Tissue Factor Total Body Surface Area Antithrombin Deficiency Smoke Inhalation Injury 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Enkhbaatar P, Traber DL (2004) Pathophysiology of acute lung injury in combined burn and smoke inhalation injury. Clin Sci (Lond) 107: 137–143CrossRefGoogle Scholar
  2. 2.
    Garcia-Avello A, Lorente JA, Cesar-Perez J, et al (1998) Degree of hypercoagulability and hyperfibrinolysis is related to organ failure and prognosis after burn trauma. Thromb Res 89: 59–64CrossRefPubMedGoogle Scholar
  3. 3.
    Niedermayr M, Schramm W, Kamolz L, et al (2007) Antithrombin deficiency and its relationship to severe burns. Burns 33: 173–178CrossRefPubMedGoogle Scholar
  4. 4.
    Rehberg S, Maybauer MO, Enkhbaatar P, Maybauer DM, Yamamoto Y, Traber DL (2009) Pathophysiology, management, and treatment of smoke inhalation injury. Expert Rev Resp Med 3: 283–297CrossRefGoogle Scholar
  5. 5.
    Hofstra JJ, Haitsma JJ, Iufferrnans NP, Levi M, Schultz MJ (2008) The role ofbronchoalveolar Hemostasis in the pathogenesis of acute lung injury. Semin Thromb Hemost 34: 475–484CrossRefPubMedGoogle Scholar
  6. 6.
    MacLaren R, Stringer KA (2007) Emerging role of anticoagulants and fibrinolytics in the treatment of acute respiratory distress syndrome. Pharmacotherapy 27: 860–873CrossRefPubMedGoogle Scholar
  7. 7.
    Schultz MJ, Haitsma JJ, Zhang H, Slutsky AS (2006) Pulmonary coagulopathy as a new target in therapeutic studies of acute lung injury or pneumonia—a review. Crit Care Med 34: 871–877PubMedGoogle Scholar
  8. 8.
    Roemisch J, Gray E, Hoffmann IN, Wiedermann CJ (2002) Antithrombin: a new look at the actions of a serine protease inhibitor. Blood Coagul Fibrinolysis 13: 657–670CrossRefPubMedGoogle Scholar
  9. 9.
    Wiedermann CJ (2006) Clinical review: molecular mechanisms underlying the role of antithrombin in sepsis. Crit Care 10: 209CrossRefPubMedGoogle Scholar
  10. 10.
    Mammen EF (1998) Antithrombin: its physiological importance and role in DIC. Semin Thromb Hemost 24: 19–25CrossRefPubMedGoogle Scholar
  11. 11.
    Edmunds T, Van Patten SM, Pollock J, et al (1998) Transgenically produced human antithrombin: structural and functional comparison to human plasma-derived antithrombin. Blood 91: 4561–4571PubMedGoogle Scholar
  12. 12.
    Olds RJ, Lane DA, Mille B, Chowdhury V, Thein SL (1994) Antithrombin: the principal inhibitor of thrombin. Semin Thromb Hemost 20: 353–372CrossRefPubMedGoogle Scholar
  13. 13.
    Nieuwenhuizen L, de Groot PG, Grutters JC, Biesma DH (2009) A review of pulmonary coagulopathy in acute lung injury, acute respiratory distress syndrome and pneumonia. Eur J Haematol 82: 413–425CrossRefPubMedGoogle Scholar
  14. 14.
    Ishii K, Chen J, Ishii M, et al (1994) Inhibition of thrombin receptor signaling by a G-protein coupled receptor kinase. Functional specificity among G-protein coupled receptor kinases. J Biol Chem 269: 1125–1130PubMedGoogle Scholar
  15. 15.
    Kaur J, Woodman RC, Ostrovsky L, Kubes P (2001) Selective recruitment of neutrophils and lymphocytes by thrombin: a role for NF-kappaB. Am J Physiol Heart Circ Physiol 281: H784–795Google Scholar
  16. 16.
    Senden NH, Jeunhomme TM, Heemskerk JW, et al (1998) Factor Xa induces cytokine production and expression of adhesion molecules by human umbilical vein endothelial cells. J Immunol 161: 4318–4324PubMedGoogle Scholar
  17. 17.
    Camerer E, Gjernes E, Wiiger M, Pringle S, Prydz H (2000) Binding of factor VIla to tissue factor on keratinocytes induces gene expression. J Biol Chem 275: 6580–6585CrossRefPubMedGoogle Scholar
  18. 18.
    Taylor FB Jr, Emerson TE Jr, Jordan R, Chang AK, Blick KE (1988) Antithrombin-III prevents the lethal effects of Escherichia coli infusion in baboons. Circ Shock 26: 227–235PubMedGoogle Scholar
  19. 19.
    Uchiba M, Okajima K, Murakami K (1998) Effects of various doses of antithrombin IlIon endotoxin-induced endothelial cell injury and coagulation abnormalities in rats. Thromb Res 89: 233–241CrossRefPubMedGoogle Scholar
  20. 20.
    Okajima K (1998) Antithrombin prevents endotoxin-induced pulmonary vascular injury by inhibiting leukocyte activation. Blood Coagul Fibrinolysis 9 (Suppl 2): S25–37Google Scholar
  21. 21.
    Woods A (2001) Syndecans: transmembrane modulators of adhesion and matrix assembly. J Clin Invest 107: 935–941CrossRefPubMedGoogle Scholar
  22. 22.
    Oelschlager C, Romisch J, Staubitz A, et al (2002) Antithrombin III inhibits nuclear factor kappaB activation in human monocytes and vascular endothelial cells. Blood 99: 4015–4020CrossRefPubMedGoogle Scholar
  23. 23.
    Neviere R, Tournoys A, Mordon S, et al (2001) Antithrombin reduces mesenteric venular leukocyte interactions and small intestine injury in endotoxemic rats. Shock 15: 220–225CrossRefPubMedGoogle Scholar
  24. 24.
    Bastarache JA, Ware LB, Bernard GR (2006) The role of the coagulation cascade in the continuum of sepsis and acute lung injury and acute respiratory distress syndrome. Semin Respir Crit Care Med 27: 365–376CrossRefPubMedGoogle Scholar
  25. 25.
    Kaneider NC, Forster E, Mosheimer B, Sturn DH, Wiedermann CJ (2003) Syndecan-4-dependent signaling in the inhibition of endotoxin-induced endothelial adherence of neutrophils by antithrombin. Thromb Haemost 90: 1150–1157PubMedGoogle Scholar
  26. 26.
    Yamashiro K, Kiryu J, Tsujikawa A, et al (2001) Inhibitory effects of antithrombin III against leukocyte rolling and infiltration during endotoxin-induced uveitis in rats. Invest Ophthalmol Vis Sci 42: 1553–1560PubMedGoogle Scholar
  27. 27.
    Souter PJ, Thomas S, Hubbard AR, Poole S, Romisch J, Gray E (2001) Antithrombin inhibits lipopolysaccharide-induced tissue factor and interleukin-6 production by mononuclear cells, human umbilical vein endothelial cells, and whole blood. Crit Care Med 29: 134–139CrossRefPubMedGoogle Scholar
  28. 28.
    Dunzendorfer S, Kaneider N, Rabensteiner A, et al (2001) Cell-surface heparan sulfate proteoglycan-mediated regulation of human neutrophil migration by the serpin antithrombin III. Blood 97: 1079–1085CrossRefPubMedGoogle Scholar
  29. 29.
    Kaneider NC, Reinisch CM, Dunzendorfer S, Romisch J, Wiedermann CJ (2002) Syndecan-4 mediates antithrombin-induced chemotaxis of human peripheral blood lymphocytes and monocytes. J Cell Sci 115: 227–236PubMedGoogle Scholar
  30. 30.
    Komura H, Uchiba M, Mizuochi Y, et al (2008) Antithrombin inhibits lipopolysaccharideinduced tumor necrosis factor-alpha production by monocytes in vitro through inhibition of Egr-1 expression. J Thromb Haemost 6: 499–507CrossRefPubMedGoogle Scholar
  31. 31.
    Harada N, Okajima K, Kushimoto S, Isobe H, Tanaka K (1999) Antithrombin reduces ischemia/ reperfusion injury of rat liver by increasing the hepatic level of prostacyclin. Blood 93: 157–164PubMedGoogle Scholar
  32. 32.
    Uchiba M, Okajima K, Murakami K, Okabe H, Takatsuki K (1996) Attenuation of endotoxininduced endothelial cell injury and coagulation abnormalities in rats. Am J Physiol 270: L921–L930PubMedGoogle Scholar
  33. 33.
    Rehberg S, Zhu Y, Yamamoto Y, et al (2009) High-dose intravenous antithrombin III reduces pulmonary vascular permeability and neutrophil count in the lymph after combined burn and smoke inhalation injury. Shock 31: O57 (abst)Google Scholar
  34. 34.
    Hofstra JJ, Cornet AD, de Rooy BF, et al (2009) Nebulized antithrombin limits bacterial outgrowth and lung injury in Streptococcus pneumoniae pneumonia in rats. Crit Care 13: R145CrossRefPubMedGoogle Scholar
  35. 35.
    Duensing TD, Wing JS, van Patten JP (1999) Sulfated polysaccharide-directed recruitment of mammalian host proteins: a novel strategy in microbial pathogenesis. Infect Immun 67: 4463–4468PubMedGoogle Scholar
  36. 36.
    Olson ST, Bjork I, Sheffer R, Craig PA, Shore JD, Choay J (1992) Role of the antithrombinbinding pentasaccharide in heparin acceleration of antithrombin-proteinase reactions. Resolution of the antithrombin conformational change contribution to heparin rate enhancement. J Biol Chem 267: 12528–12538PubMedGoogle Scholar
  37. 37.
    Justus AC, Roussev R, Norcross JL, Faulk WP (1995) Antithrombin binding by human umbilical vein endothelial cells: effects of exogenous heparin. Thromb Res 79: 175–186CrossRefPubMedGoogle Scholar
  38. 38.
    Warren BL, Eid A, Singer P, et al (2001) Caring for the critically ill patient. High-dose antithrombin III in severe sepsis: a randomized controlled trial. JAMA 286: 1869–1178CrossRefPubMedGoogle Scholar
  39. 39.
    Murakami K, McGuire R, Cox RA, et al (2003) Recombinant antithrombin attenuates pulmonary inflammation following smoke inhalation and pneumonia in sheep. Crit Care Med 31: 577–583CrossRefPubMedGoogle Scholar
  40. 40.
    Enkhbaatar P, Cox RA, Traber LD, et al (2007) Aerosolized anticoagulants ameliorate acute lung injury in sheep after exposure to burn and smoke inhalation. Crit Care Med 35: 2805–2810CrossRefPubMedGoogle Scholar
  41. 41.
    Enkhbaatar P, Esechie A, Wang J, et al (2008) Combined anticoagulants ameliorate acute lung injury in sheep after burn and smoke inhalation. Clin Sci (Lond) 114: 321–329CrossRefGoogle Scholar
  42. 42.
    Kowal-Vern A, McGill V, Walenga JM, Gamelli RL (2000) Antithrombin III concentrate in the acute phase of thermal injury. Burns 26: 97–101CrossRefPubMedGoogle Scholar
  43. 43.
    Kowal-Vern A, McGill V, Walenga JM, Gamelli RL (2000) Antithrombin (H) concentrate infusions are safe and effective in patients with thermal injuries. J Burn Care Rehabil 21: 115–127CrossRefPubMedGoogle Scholar
  44. 44.
    Kowal-Vern A, Walenga JM, McGill V, Gamelli RL (2001) The impact of antithrombin (H) concentrate infusions on pulmonary function in the acute phase of thermal injury. Burns 27: 52–60CrossRefPubMedGoogle Scholar
  45. 45.
    Kowal-Vern A, Latenser BA (2003) Antithrombin (human, concentrate infusion in pediatric patients with < 50 % TBSA burns. Burns 29: 615–618CrossRefPubMedGoogle Scholar
  46. 46.
    Del Principe D (2003) Antithrombin III in burned children. Minerva Anestesiol 69: 367–380Google Scholar
  47. 47.
    Lavrentieva A, Kontakiotis T, Bitzani M, et al (2008) Early coagulation disorders after severe burn injury: impact on mortality. Intensive Care Med 34: 700–706CrossRefPubMedGoogle Scholar
  48. 48.
    Lavrentieva A, Kontakiotis T, Bitzani M, et al (2008) The efficacy of antithrombin administration in the acute phase of burn injury. Thromb Haemost 100: 286–290PubMedGoogle Scholar
  49. 49.
    Rehberg S, Enkhbaatar P, Traber DL (2008) Anticoagulant therapy in acute lung injury: a useful tool without proper operating instruction? Crit Care 12: 179CrossRefPubMedGoogle Scholar
  50. 50.
    Kipnis E, Guery BP, Tournoys A, et al (2004) Massive alveolar thrombin activation in Pseudomonas aeruginosa-induced acute lung injury. Shock 21: 444–451CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science + Business Media Inc. 2010

Authors and Affiliations

  • S. Rehberg
    • 1
  • D. L. Traber
    • 1
  • P. Enkhbaatar
    • 1
  1. 1.Investigational Intensive Care Unit Department of AnesthesiologyThe University of Texas Medical BranchGalvestonUSA

Personalised recommendations